Thermo Fisher Scientific Inc. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. The filing reports full-year results and quarterly data, including Q4; it is not a standalone Q4 report. Thermo Fisher supplies scientific instruments, laboratory products, diagnostics, and pharmaceutical development, manufacturing, and clinical-trial services through four segments.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $20.92 billion | $18.27 billion |
| Operating income | $2.97 billion; 14.2% margin | $2.45 billion; 13.4% margin |
| Income from continuing operations | $2.23 billion | $2.03 billion |
| Net income | $2.23 billion | $2.02 billion |
| Diluted EPS | $5.59 | $5.09 |
| Cash provided by operating activities | $4.01 billion | $3.26 billion |
| Capital expenditures | $508 million | $444 million |
Revenue increased 14% year over year. Acquisitions contributed $1.63 billion and favorable currency translation $70 million; growth excluding acquisitions and currency was $949 million, or 5%, primarily from higher demand. Cash from operations less capital expenditures was approximately $3.50 billion in 2017.
At year-end, cash and cash equivalents were $1.34 billion, working capital was $2.37 billion, and debt carrying value was $21.01 billion, including $2.14 billion of short-term obligations and current maturities. The $2.50 billion revolving credit facility had no borrowings outstanding; approximately $77 million of capacity was reserved for letters of credit. Management said cash, operating cash flow, and available credit should cover existing-business needs for at least 24 months.
Segment revenues were $5.73 billion for Life Sciences Solutions, $4.82 billion for Analytical Instruments, $3.49 billion for Specialty Diagnostics, and $7.83 billion for Laboratory Products and Services. Segment income is a company-defined measure that excludes specified acquisition, restructuring, and amortization items. Segment operating margins were 33.1%, 21.3%, 26.7%, and 12.9%, respectively.
Material changes and unusual items
- Patheon was acquired in August 2017 for $7.36 billion, including assumed net debt, adding pharmaceutical contract development and manufacturing services. Its post-acquisition 2017 revenue was $722 million; it recorded an operating loss of $108 million, primarily from acquisition and restructuring charges.
- Analytical Instruments revenue grew 31%, reflecting acquisitions including FEI and operating growth. Laboratory Products and Services revenue grew 16%, with Patheon a major contributor; its margin declined from 14.4% to 12.9%, primarily due to sales mix and growth investments.
- Research and development expense rose to $888 million from $755 million. Restructuring and other costs totaled $298 million, compared with $395 million in 2016. The company identified approximately $105 million of additional restructuring charges, primarily in 2018, and expected about $90 million of annual savings from 2017 actions.
- The Tax Act produced a provisional net tax charge of $204 million, including a $1.25 billion transition-tax charge and a $1.06 billion benefit from remeasuring deferred taxes. Other tax items included a $237 million benefit from refinancing intercompany debt and a $65 million benefit from extending a Singapore tax holiday. The 2017 income-tax provision was $201 million; cash income taxes paid were $479 million.
- A fourth-quarter out-of-period tax-accounting adjustment increased 2017 comprehensive income by $101 million. The company said it did not affect net income or cash flows and was not material to previously reported periods.
Q4, outlook, and risks
Q4 2017 revenue was $6.05 billion, compared with $4.95 billion in Q4 2016. Net income was $528 million versus $630 million, and diluted EPS was $1.30 versus $1.59. The filing’s quarterly table reports restructuring and other costs of $51 million in Q4 2017 and $98 million in Q4 2016.
Management forecast a 2018 effective tax rate of 6%–9% and capital expenditures of $700–$730 million. The filing provides no clear full-year 2018 revenue or EPS guidance. Management cited moderate sales growth in North America and Europe and particularly strong growth in Asia during 2017.
- Debt and covenant exposure: the credit facility’s maximum leverage ratio steps down to 3.5:1.0 from Q3 2018; the minimum interest coverage ratio is 3.0:1.0.
- Acquisition integration and impairment: goodwill was $25.29 billion. The Patheon reporting unit had $3.25 billion of goodwill and a carrying value of $7.33 billion; management noted relatively small reductions in anticipated cash flows could result in impairment.
- Tax uncertainty: Tax Act accounting amounts were provisional; unrecognized tax benefits totaled $1.41 billion. The company also had $13.21 billion of foreign undistributed earnings intended to remain invested abroad.
- Contingencies: environmental liabilities were $52 million. Product liability, workers’ compensation, and other personal-injury accruals were $220 million, with estimated insurer recoveries recorded separately. Promega litigation had a $52 million accrual despite a favorable appellate decision; further review remained possible.
- Other disclosed risks include regulatory and quality requirements in pharma services, intellectual-property claims, product liability, foreign exchange, customer and government spending, supply and site disruptions, and cybersecurity.
Key facts for investors to verify
- How much of growth and future profitability is attributable to acquisitions, especially Patheon, versus organic demand; confirm Patheon integration costs and margin trajectory.
- Whether the 2018 tax-rate outlook and provisional Tax Act estimates hold as tax accounting is finalized.
- Debt repayment capacity, covenant headroom, refinancing needs, and the effect of acquisition-related interest costs.
- Whether restructuring charges deliver the expected savings and whether Laboratory Products and Services margins recover.
- Developments in the Promega matter, other litigation, environmental remediation, and the company’s substantial goodwill and intangible-asset impairment sensitivity.